Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours

IGF-1R as an anti-cancer target--trials and tribulations

(2013) Helen X. Chen et al.   Chinese Journal of Cancer

Targeting the Insulin Growth Factor Receptor 1

(2012) Fernanda I. Arnaldez et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

(2011) J. Gao et al.   CANCER RESEARCH

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

(2011) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy

(2010) J. Zha et al.   CLINICAL CANCER RESEARCH

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

(2008) John SP Yuen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer

(2008) P. D. Ryan et al.   ONCOLOGIST